Solventum

SOLV · NYSE

$86.39+$1.34 (+1.58%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $85.05

Latest news

NewsOct 19, 4:07 PM ET
Solventum Receives FDA Clearance For Combined Use Of Restrata Synthetic Electrospun Fiber Matrix, Solventum V.A.C. Therapy
Press releaseOct 19, 4:05 PM ETPRNewswire
Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*
Press releaseOct 15, 4:05 PM ETPRNewswire
Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026
Press releaseOct 6, 9:06 AM ETGlobe Newswire
Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.
Press releaseSep 2, 4:05 PM ETPRNewswire
Solventum to Participate in the 2026 Wells Fargo Healthcare Conference
Press releaseAug 12, 9:15 AM ETGlobe Newswire
The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
NewsAug 5, 4:19 PM ET
Solventum Q2 Adj. EPS $2.55 Beats $1.91 Estimate, Sales $2.209B Beat $2.156B Estimate
Press releaseAug 5, 4:12 PM ETPRNewswire
Solventum Reports Second Quarter 2026 Financial Results
Press releaseAug 5, 4:05 PM ETPRNewswire
Solventum Announces Intent to Separate its Health Information Systems Business
Press releaseJul 15, 4:05 PM ETPRNewswire
Solventum to Report Second Quarter Fiscal 2026 Earnings on August 5, 2026
Press releaseMay 27, 4:05 PM ETPRNewswire
Solventum to Participate in the 2026 Jefferies Healthcare Conference
Press releaseMay 7, 4:05 PM ETPRNewswire
Solventum to Participate in the 2026 BofA Securities Health Care Conference
NewsMay 5, 5:34 PM ET
Solventum Q1 2026 Earnings Call: Complete Transcript
NewsMay 5, 4:06 PM ET
Solventum Q1 Adj. EPS $1.48 Beats $1.35 Estimate, Sales $2.007B Beat $1.967B Estimate
Press releaseMay 5, 4:05 PM ETPRNewswire
Solventum Reports First Quarter 2026 Financial Results
NewsMay 5, 7:12 AM ET
Earnings Scheduled For May 5, 2026
NewsApr 30, 3:12 PM ETEvette Mitkov
Solventum Stock Is Recovering: What's Going On?
Press releaseApr 30, 1:05 PM ETGlobe Newswire
Trian Calls on Solventum's Board to Create Value; Publishes Open Letter and Slide Deck
Press releaseApr 14, 4:05 PM ETPRNewswire
Solventum to Report First Quarter Fiscal 2026 Earnings on May 5, 2026
Press releaseMar 11, 4:05 PM ETPRNewswire
Solventum to Participate in the 2026 KeyBanc Healthcare Forum
Press releaseMar 6, 7:00 AM ETBusiness Wire
Middleby Appoints Glenn Eisenberg To Board of Directors
Press releaseFeb 26, 4:05 PM ETPRNewswire
Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance
Press releaseFeb 3, 4:05 PM ETPRNewswire
Solventum to Report Fourth Quarter and Full Year Fiscal 2025 Earnings on February 26, 2026
NewsJan 28, 12:00 PM ET
P/E Ratio Insights for Solventum
Press releaseDec 23, 4:05 PM ETPRNewswire
Solventum Completes Acquisition of Acera Surgical
Press releaseDec 17, 4:05 PM ETPRNewswire
Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy
Press releaseDec 16, 4:05 PM ETPRNewswire
Solventum Earns Diamond Level HIRC Resiliency Badge, Demonstrating Best-In-Class Supply Chain Strength
NewsDec 2, 8:43 AM ETAvi Kapoor
This T-Mobile Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday
Press releaseNov 25, 4:05 PM ETPRNewswire
Solventum to Participate in the 2025 Piper Sandler Healthcare Conference
Press releaseNov 20, 9:00 AM ETPRNewswire
Solventum Announces Agreement to Acquire Acera Surgical
Press releaseNov 20, 9:00 AM ETPRNewswire
Solventum Announces $1 Billion Share Repurchase Program
Press releaseNov 6, 4:05 PM ETPRNewswire
Solventum Reports Third Quarter 2025 Financial Results
NewsNov 6, 6:12 AM ET
Earnings Scheduled For November 6, 2025
NewsNov 5, 10:01 AM ET
Examining the Future: Solventum's Earnings Outlook
Press releaseNov 3, 4:05 PM ETPRNewswire
Solventum to Participate in the 2025 Stifel Healthcare Conference
Press releaseOct 21, 5:00 PM ETPRNewswire
Solventum Appoints Heather Knight as Chief Commercial Officer
NewsMay 8, 4:33 AM ET
Earnings Scheduled For May 8, 2025
NewsApr 24, 11:19 AM ETTim Melvin
Alpha Buying: Big Oil Becomes Ground Zero for Activist Investing in 2025
NewsMar 20, 9:11 AM ET
Solventum To Present Value Creation Formula And Long-Range Plan At Investor Day; Accelerate Organic Sales Growth Of 4%-5% In 2028; Expand Operating Margins To Be 23%-25% In 2028; Generate EPS CAGR Of 10% Over The 3-Year Period Ending 2028; Drive Free Cash Flow Conversion Of 80%+
Press releaseMar 20, 9:00 AM ETPRNewswire
Solventum to Present Value Creation Formula and Long-Range Plan at 2025 Investor Day
Press releaseJan 8, 1:01 PM ETGlobe Newswire
Trian Issues Open Letter to Solventum Shareholders

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Solventum Receives FDA Clearance For Combined Use Of Restrata Synthetic Electrospun Fiber Matrix, Solventum V.A.C. Therapy

Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*

Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Solventum to Participate in the 2026 Wells Fargo Healthcare Conference

The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For

Solventum Q2 Adj. EPS $2.55 Beats $1.91 Estimate, Sales $2.209B Beat $2.156B Estimate

Solventum Reports Second Quarter 2026 Financial Results

Solventum Announces Intent to Separate its Health Information Systems Business

Solventum to Report Second Quarter Fiscal 2026 Earnings on August 5, 2026

Solventum to Participate in the 2026 Jefferies Healthcare Conference

Solventum to Participate in the 2026 BofA Securities Health Care Conference

Solventum Q1 2026 Earnings Call: Complete Transcript

Solventum Q1 Adj. EPS $1.48 Beats $1.35 Estimate, Sales $2.007B Beat $1.967B Estimate

Solventum Reports First Quarter 2026 Financial Results

Earnings Scheduled For May 5, 2026

Solventum Stock Is Recovering: What's Going On?

Trian Calls on Solventum's Board to Create Value; Publishes Open Letter and Slide Deck

Solventum to Report First Quarter Fiscal 2026 Earnings on May 5, 2026

Solventum to Participate in the 2026 KeyBanc Healthcare Forum

Middleby Appoints Glenn Eisenberg To Board of Directors

Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance

Solventum to Report Fourth Quarter and Full Year Fiscal 2025 Earnings on February 26, 2026

P/E Ratio Insights for Solventum

Solventum Completes Acquisition of Acera Surgical

Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy

Solventum Earns Diamond Level HIRC Resiliency Badge, Demonstrating Best-In-Class Supply Chain Strength

This T-Mobile Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday

Solventum to Participate in the 2025 Piper Sandler Healthcare Conference

Solventum Announces Agreement to Acquire Acera Surgical

Solventum Announces $1 Billion Share Repurchase Program

Solventum Reports Third Quarter 2025 Financial Results

Earnings Scheduled For November 6, 2025

Examining the Future: Solventum's Earnings Outlook

Solventum to Participate in the 2025 Stifel Healthcare Conference

Solventum Appoints Heather Knight as Chief Commercial Officer

Earnings Scheduled For May 8, 2025

Alpha Buying: Big Oil Becomes Ground Zero for Activist Investing in 2025

Solventum To Present Value Creation Formula And Long-Range Plan At Investor Day; Accelerate Organic Sales Growth Of 4%-5% In 2028; Expand Operating Margins To Be 23%-25% In 2028; Generate EPS CAGR Of 10% Over The 3-Year Period Ending 2028; Drive Free Cash Flow Conversion Of 80%+

Solventum to Present Value Creation Formula and Long-Range Plan at 2025 Investor Day

Trian Issues Open Letter to Solventum Shareholders